Operational Costs Compared: SG&A Analysis of MannKind Corporation and Galapagos NV

A Decade of SG&A: MannKind vs. Galapagos

In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, MannKind Corporation and Galapagos NV have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Galapagos NV's SG&A expenses surged by over 900%, peaking in 2022. This reflects their aggressive expansion and investment in R&D. In contrast, MannKind Corporation maintained a more stable trajectory, with expenses fluctuating modestly around an average of $78 million annually. Notably, 2023 marked a convergence, with both companies reporting nearly identical SG&A costs. This alignment could signal a strategic shift or market adaptation. As investors and analysts scrutinize these trends, understanding the nuances of SG&A management becomes crucial for predicting future growth and sustainability in the biotech sector.